Platelet activation signaling pathways

Platelet activation signaling pathways are the complex intracellular networks that regulate platelet responses to vascular injury, including adhesion, shape change, and aggregation [1]. These pathways are triggered by various agonists such as thrombin, collagen, and adenosine diphosphate (ADP) binding to specific surface receptors like PAR-1, GPVI, and P2Y12 [2]. Downstream signaling involves the activation of phospholipase C, mobilization of intracellular calcium, and the activation of protein kinase C, which ultimately leads to the conformational change of the integrin alpha-IIb/beta-3 receptor [3]. This integrin activation is the final common pathway for platelet aggregation, allowing fibrinogen to bridge adjacent platelets [4]. While essential for normal hemostasis, excessive activation of these pathways is a primary driver of arterial thrombosis, which can cause myocardial infarction and ischemic stroke [5]. Pharmacological agents target various components of these pathways, such as COX-1 (aspirin), P2Y12 (clopidogrel), and GP IIb/IIIa (abciximab), to prevent thrombotic events [6]. The clinical utility of targeting these pathways is well-established in cardiovascular medicine, though it requires careful management to minimize the risk of major bleeding [7]. Modern research continues to explore more specific nodes within these pathways to improve the efficacy-to-safety ratio of antiplatelet therapies [8].

Other names

Platelet activationPlatelet aggregation pathwaysHemostatic signaling cascade

Inhibition of cyclooxygenase-1 (COX-1), antagonism of P2Y12 purinergic receptors, blockade of Glycoprotein IIb/IIIa receptors, and antagonism of Protease-activated receptor 1 (PAR-1) [5][6].